40results about How to "High antibody activity" patented technology

Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided.

The invention discloses pumpkin powder with a blood sugar reducing effect. The pumpkin powder is characterized by consisting of the following components in percentage by weight: 10-50 percent of pumpkin powder, 0.4-3 percent of a mulberry extract, 0.4-3 percent of a puerarin extract, 0.3-2 permillage of an astragalus membranaceus extract, 2-12 percent of rhizoma anemarrhenae powder, 3-15 percent of ligustrum lucidum ait powder, 1-10 percent of purslane powder, 5-20 percent of resistant dextrin, 1-10 percent of L-arabinose, 1-6 percent of xylitol, 0.5-4 percent of xylooligosaccharide, 0.01-0.05 permillage of vitamin A, 0.01-0.05 permillage of vitamin B1, 0.01-0.05 permillage of vitamin B2, 0.01-0.05 permillage of vitamin B6, 0.01-0.05 permillage of folic acid, 1-5 permillage of vitamin C, 0.0001-0.0005 permillage of vitamin D, 0.1-0.5 permillage of vitamin E and the balance of citric acid. The pumpkin powder can be used for reducing the blood sugar of a diabetes patient and reducing the diabetic complications and has the effects of enhancing the immunity of the organism, resisting oxidization and promoting the organism to produce nutritional substances.

[Problems] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity.

[Means for Solving Problems] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.

The invention relates to a preparation method of fluorescence antibody for detecting a Newcastle disease virus and a solid-phase immunofluorescence detection assay kit. The preparation method comprises the following steps of: respectively deriving R-phycoerythrin (RPE) and an antibody resisting the Newcastle disease virus (NDV) by using a cross-linking agent SPDP (N-succinimidyl-3-(2-pyridyldithiol) propionate), cross-linking the derivatives in a proper molar ratio, and purifying through HPLC (High Performance Liquid Chromatography) to prepare an RPE marked NDV fluorescence antibody. The solid-phase immunofluorescence detection assay kit is formed from the fluorescence antibody, an NDV-resisting antibody, an agarose microsphere, diluted hydrochloric acid and a washing liquid. The assay kit comprises the following detection flows of: coating an activated microsphere with the antibody, washing, combining with a sample to be measured, washing, combining with the fluorescence antibody, fully washing, exciting by blue and green light in a fluorescence microscope, observing and judging the result. The prepared fluorescence antibody has the advantages of high yield, high purity, bright orange fluorescence and good stability; and the assay kit has signal enrichment action by using a spherical carrier and can increase detection sensitivity. The invention is applicable to the rapid detection of the Newcastle disease virus.

The invention relates to a method for preparing a fluorescent antibody for detecting avian influenza virus and a solid phase immunofluorescence detection kit. According to the invention, an avian influenza virus antibody is marked by allophycocyanin (APC) so as to prepare the avian influenza virus fluorescent antibody; the APC and the antibody are derived by a chemical cross-linking agent SPDP respectively; the derivatives are subjected to liquid phase cross-linking in a proper molar ratio; and then the fluorescent antibody is prepared by high pressure liquid chromatography purification. The solid phase immunofluorescence detection kit comprises the fluorescent antibody, CNBr activated agarose microspheres, the avian influenza virus antibody, cleaning solution and the like. The using method of the kit comprises the following steps of: activating a microsphere carrier and then coating the activated microsphere carrier by using the avian influenza virus antibody; cleaning; combining the microspheres coated with the antibody with a sample (an antigen) to be detected; combining the microspheres coated with the antibody with the fluorescent antibody after cleaning; removing the uncombined fluorescent antibody by cleaning; and observing under a fluorescence microscope and determining the result. The fluorescent antibody prepared by the method is characterized by high cross-linking efficiency, high purity, bright red fluorescence and stable performance. The microsphere solid phase carrier which is adopted by the kit can obviously improve fluorescent detection sensitivity, and is suitable for the quick detection of the avian influenza virus.

Provided are novel complexes containing a crosslinked avidin, an analyzing method and analyzing reagents and kits whereby a compound to be analyzed can be quickly, conveniently and accurately analyzed while taking advantage of the avidin-biotin reaction. The complexes contain at least two homogeneous or heterogeneous biotin-introduced products and one crosslinked avidin sandwiched therebetween. In the analyzing method, the homogeneous or heterogeneous biotin-introduced products and the crosslinked avidin are used. The analyzing reagent contains the crosslinked avidin. The analyzing kit contains the crosslinked avidin and a biotinylating agent.

The invention discloses a polypeptide, and belongs to the field of biomedicine. In order to solve the problems of complicated production process, high cost and low targeting existing in existing methods for enhancing the targeting of T cells, the invention provides the polypeptide. The polypeptide can significantly enhance the targeting of immune cells. At the same time, the preparation process ofthe polypeptide is simple, and the cost is lower than the existing cost of preparing CAR-T cells or the existing cost of preparing bispecific antibody cells.

The invention relates to a method for preparing enterobacteria specific immunity milk product which contains enterobacteria specific IgY antibody. The preparation comprises that first cultivating single enterobacteria or various viruses, preparing single or composite antigen, then using the antigen to process high-immunity ejection into egg-laying bird, checking the immunity egg, preparing enterobacteria specific IgY or enterobacteria specific composite IgY, purifying, filtering into the final product, mixing the product with some milk powder, to obtain immunity milk product. The invention can effectively resolve the problem of infant milk powder that polluted by enterobacteria and salmonella.

The invention discloses a preparation method of chicken adenovirus egg yolk antibody whole egg spray-dried powder. The preparation method comprises the following steps: injecting an adenovirus vaccineinto laying hens, carrying out immunological detection on egg yolk antibodies in egg yolk, and collecting eggs when the agar diffusion titer of the egg yolk antibodies of adenovirus reaches 1:15 or above; and cleaning and disinfecting the collected eggs, beating the eggs under a sterile condition, adding water into the whole egg liquid, performing stirring, separately carrying out steps of yeastsugar removal and protein digestion by pepsase, and then carrying out warm bath, cooling, and carrying out spray drying to obtain the product. The whole egg antibody powder obtained by the preparationmethod provided by the invention is good in solubility, low in antibody loss and high in antibody activity, cost is greatly reduced, and the whole egg antibody powder has relatively good economic andsocial benefits.

The present invention pertains to a method for controlling the circulation half-life of antibodies by adjusting the amount of sialic acid in the carbohydrates attached to the Fab part of the antibodies. Furthermore, the present invention provides antibodies having an increased circulation half-life.

The present disclosure relates to methods for reducing the oxidation level of cysteine residues in recombinant polypeptides such as anti-IL-17 antibodies during cell culture (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of recombinant polypeptides such as anti-IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab. Also provided are purified preparations of recombinant polypeptides produced by such methods wherein the level of active recombinant polypeptide in the preparation is high.